Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity

British Journal of Pharmacology

Volumn 164, Issue 5, 2011, Pages 1433-1444

  Raviv, Z ^a   Zilberberg, A ^a   Cohen, S ^a   Reischer Pelech, D ^a   Horrix, C ^b   Berger, M R ^b   Rosin Arbesfeld, R ^a   Flescher, E ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

apoptosis; colorectal cancer; methyl jasmonate; sensitization; survivin; TRAIL

Indexed keywords

BETA CATENIN; CASPASE; CYTOCHROME C; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; JASMONIC ACID METHYL ESTER; LUCIFERASE; MESSENGER RNA; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR D; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIZATION; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICROSCOPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ACETIC ACIDS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOPENTANES; CYTOCHROMES C; DOWN-REGULATION; DRUG SYNERGISM; FLOW CYTOMETRY; GENES, REPORTER; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUCIFERASES; OXYLIPINS; RECEPTORS, DEATH DOMAIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 80054022978     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01419.x     Document Type: Article

References (45)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Ashkenazi A, Herbst RS, (2008). To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118: 1979-1990. (Pubitemid 351872316)
3. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC, (2004). Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915-923. (Pubitemid 39139750)
4. Falschlehner C, Emmerich CH, Gerlach B, Walczak H, (2007). TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475. (Pubitemid 47031030)
5. Fingrut O, Flescher E, (2002). Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 16: 608-616. (Pubitemid 34449741)
6. Gazit A, Yaniv A, Bafico A, Pramila T, Igarashi M, Kitajewski J, et al,. (1999). Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response. Oncogene 18: 5959-5966. (Pubitemid 29535007)
7. Goda AE, Yoshida T, Horinaka M, Yasuda T, Shiraishi T, Wakada M, et al,. (2008). Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 27: 3435-3445. (Pubitemid 351769318)
8. Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T, et al,. (2008). Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27: 4636-4643.
9. Goldoni M, Johansson C, (2007). A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro 21: 759-769. (Pubitemid 46603249)
10. Hasegawa H, Ueda M, Furukawa K, Watanabe M, Teramoto T, Mukai M, et al,. (1995). p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence. Int J Cancer 64: 47-51.
11. Hernandez A, Wang QD, Schwartz SA, Evers BM, (2001). Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg 5: 56-65. (Pubitemid 33651239)
12. Ishii Y, Kiyota H, Sakai S, Honma Y, (2004). Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones. Leukemia 18: 1413-1419. (Pubitemid 39136752)
13. Johnstone RW, Frew AJ, Smyth MJ, (2008). The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
14. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N, (1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074. (Pubitemid 28521163)
15. Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS, (2008). Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res 68: 266-275. (Pubitemid 351380128)
16. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC, (2003). Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-209. (Pubitemid 36859937)
17. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A, (2000). Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620.
18. Klein PS, Melton DA, (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93: 8455-8459. (Pubitemid 26269579)
19. Koschny R, Walczak H, Ganten TM, (2007). The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 85: 923-935. (Pubitemid 47282789)
20. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG, (2008). IAP-targeted therapies for cancer. Oncogene 27: 6252-6275.
21. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al,. (2002). Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274-281. (Pubitemid 34250106)
22. LeBlanc HN, Ashkenazi A, (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75. (Pubitemid 36511833)
23. Li H, Pamukcu R, Thompson WJ, (2002). beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther 1: 621-625.
24. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X, (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490. (Pubitemid 28391864)
25. Midgley R, Kerr D, (1999). Colorectal cancer. Lancet 353: 391-399. (Pubitemid 29088178)
26. Midgley RS, Kerr DJ, (2000). ABC of colorectal cancer: adjuvant therapy. BMJ 321: 1208-1211.
27. Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, et al,. (2007). Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res 142: 281-286. (Pubitemid 47418828)
28. Ozoren N, El-Deiry WS, (2002). Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4: 551-557. (Pubitemid 35417080)
29. Palacios C, Yerbes R, Lopez-Rivas A, (2006). Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 66: 8858-8869. (Pubitemid 44449204)
30. Pirnia F, Schneider E, Betticher DC, Borner MM, (2002). Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ 9: 905-914. (Pubitemid 35023606)
31. Polakis P, (2000). Wnt signaling and cancer. Genes Dev 14: 1837-1851. (Pubitemid 30639518)
32. Reischer D, Heyfets A, Shimony S, Nordenberg J, Kashman Y, Flescher E, (2007). Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma. Br J Pharmacol 150: 738-749. (Pubitemid 46440216)
33. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, et al,. (2004). Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 24: 8541-8555. (Pubitemid 39245075)
34. Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E, (2005). Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 65: 1984-1993. (Pubitemid 40478628)
35. Roth W, Reed JC, (2004). FLIP protein and TRAIL-induced apoptosis. Vitam Horm 67: 189-206. (Pubitemid 39753664)
36. Rougier P, Mitry E, (2003). Epidemiology, treatment and chemoprevention in colorectal cancer. Ann Oncol 14 (Suppl. 2): ii3-ii5. (Pubitemid 36874131)
37. Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, Wiestler O, et al,. (2006). Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 11: 1503-1512. (Pubitemid 44253668)
38. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al,. (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609.
39. Tong QS, Jiang GS, Zheng LD, Tang ST, Cai JB, Liu Y, et al,. (2008). Natural jasmonates of different structures suppress the growth of human neuroblastoma cell line SH-SY5Y and its mechanisms. Acta Pharmacol Sin 29: 861-869.
40. Van Geelen CM, de Vries EG, de Jong S, (2004). Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7: 345-358. (Pubitemid 40341956)
41. Wang Z, Sampath J, Fukuda S, Pelus LM, (2005). Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res 65: 8224-8232. (Pubitemid 41330586)
42. Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, Yamanaka Y, et al,. (2005). Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep 14: 1311-1316.
43. Yoo J, Lee YJ, (2007). Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol 72: 1586-1592. (Pubitemid 350146095)
44. Zhang M, Yang J, Li F, (2006). Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res 25: 391-402. (Pubitemid 44763731)
45. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, et al,. (2001). Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667. (Pubitemid 34013874)